{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:27:46Z","timestamp":1789993666824,"version":"4.0.1"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,13]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening, hyperinflammatory disorder, characterized by multiorgan failure, fever and cytopenias. The diagnosis of HLH and its subtype Macrophage Activation Syndrome (MAS) remains a challenge. Interleukin 18 (IL-18) is emerging as a potential biomarker for HLH\/MAS but is currently not a part of diagnostic criteria. This systematic review aimed to assess the potential role of IL-18 in the diagnosis and monitoring of HLH and MAS, and was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. PubMed and Embase were searched on 30\u00a0January 2020. Studies included all subtypes of HLH and a range of underlying disorders in both children and adults. A total of 14 studies were included. Generally, serum IL-18 was elevated in both primary and secondary HLH (&amp;gt;\u00a01000\u00a0pg\/ml) compared with other inflammatory conditions and with healthy individuals; thus, serum IL-18 may be able to discriminate between HLH and other inflammatory conditions. Significantly increased IL-18 (&amp;gt;\u00a010\u00a0000\u00a0pg\/ml) was also consistently described in MAS compared with other subtypes of HLH. The ability of IL-18 to distinguish MAS from systemic juvenile idiopathic arthritis (JIA) is less unambiguous, as IL-18 levels &amp;gt;\u00a0100\u00a0000\u00a0pg\/ml were described in sJIA patients both with and without MAS. IL-18 may help to differentiate between HLH subtypes and other inflammatory conditions. As HLH and MAS are rare disorders, only few and relatively small studies exist on the subject. Larger, prospective multi-center studies are called for to assess the diagnostic precision of IL-18 for HLH and MAS.<\/jats:p>","DOI":"10.1111\/cei.13543","type":"journal-article","created":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T12:15:32Z","timestamp":1604146532000},"page":"174-182","source":"Crossref","is-referenced-by-count":63,"title":["The role of interleukin-18 in the diagnosis and monitoring of hemophagocytic lymphohistiocytosis\/macrophage activation syndrome \u2013 a systematic review"],"prefix":"10.1093","volume":"203","author":[{"given":"J M","family":"Krei","sequence":"first","affiliation":[{"name":"Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H J","family":"M\u00f8ller","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Department of Clinical Medicine, Aarhus University, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2978-5185","authenticated-orcid":false,"given":"J B","family":"Larsen","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,23]]},"reference":[{"key":"2021121023214974400_cei13543-bib-0001","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev-pathol-020117-043625","article-title":"Hemophagocytic lymphohistiocytosis","volume":"13","author":"Al-Samkari","year":"2018","journal-title":"Annu Rev Pathol"},{"key":"2021121023214974400_cei13543-bib-0002","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"2021121023214974400_cei13543-bib-0003","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/pbc.22774","article-title":"Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality","volume":"56","author":"Lin","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"2021121023214974400_cei13543-bib-0004","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fimmu.2019.00119","article-title":"The immunology of macrophage activation syndrome","volume":"10","author":"Crayne","year":"2019","journal-title":"Front Immunol"},{"key":"2021121023214974400_cei13543-bib-0005","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1126\/science.286.5446.1957","article-title":"Perforin gene defects in familial hemophagocytic lymphohistiocytosis","volume":"286","author":"Stepp","year":"1999","journal-title":"Science"},{"key":"2021121023214974400_cei13543-bib-0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2017.03.023","article-title":"Similar but not the same: differential diagnosis of HLH and sepsis","volume":"114","author":"Machowicz","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021121023214974400_cei13543-bib-0007","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.1542\/neo.20-6-e316","article-title":"Neonatal hemophagocytic lymphohistiocytosis","volume":"20","author":"McLean","year":"2019","journal-title":"Neoreviews"},{"key":"2021121023214974400_cei13543-bib-0008","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/intimm\/dxy012","article-title":"Convergent pathways of the hyperferritinemic syndromes","volume":"30","author":"Schulert","year":"2018","journal-title":"Int Immunol"},{"key":"2021121023214974400_cei13543-bib-0009","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.3389\/fimmu.2017.01902","article-title":"Epstein\u2013Barr virus and hemophagocytic lymphohistiocytosis","volume":"8","author":"Marsh","year":"2018","journal-title":"Front Immunol"},{"key":"2021121023214974400_cei13543-bib-0010","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1309\/AJCPMD5TJEFOOVBW","article-title":"Marrow assessment for hemophagocytic lymphohistiocytosis demonstrates poor correlation with disease probability","volume":"141","author":"Ho","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"2021121023214974400_cei13543-bib-0011","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/intimm\/dxx031","article-title":"Hyperferritinemia and inflammation","volume":"29","author":"Kernan","year":"2017","journal-title":"Int Immunol"},{"key":"2021121023214974400_cei13543-bib-0012","doi-asserted-by":"crossref","first-page":"6103064","DOI":"10.1155\/2018\/6103064","article-title":"Soluble Interleukin-2 receptor: a potential marker for monitoring disease activity in IgG4-related disease","volume":"2018","author":"Karim","year":"2018","journal-title":"Mediat Inflamm"},{"key":"2021121023214974400_cei13543-bib-0013","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/imr.12616","article-title":"Interleukin-18: biological properties and role in disease pathogenesis","volume":"281","author":"Kaplanski","year":"2018","journal-title":"Immunol Rev"},{"key":"2021121023214974400_cei13543-bib-0014","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1002\/eji.1830271107","article-title":"Comparison of the effects of interleukin-1 alpha, interleukin-1 beta and interferon-gamma-inducing factor on the production of interferon-gamma by natural killer","volume":"27","author":"Hunter","year":"1997","journal-title":"Eur J Immunol"},{"key":"2021121023214974400_cei13543-bib-0015","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/blood-2017-12-820852","article-title":"Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome","volume":"131","author":"Weiss","year":"2018","journal-title":"Blood"},{"key":"2021121023214974400_cei13543-bib-0016","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2019.008","article-title":"Soluble ST2 and CD163 as potential biomarkers to differentiate primary hemophagocytic lymphohistiocytosis from macrophage activation syndrome","volume":"11","author":"Gao","year":"2019","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2021121023214974400_cei13543-bib-0017","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1182\/blood-2005-05-1980","article-title":"Severe imbalance of IL-18\/IL-18BP in patients with secondary hemophagocytic syndrome","volume":"106","author":"Mazodier","year":"2005","journal-title":"Blood"},{"key":"2021121023214974400_cei13543-bib-0018","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cyto.2019.03.018","article-title":"Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile idiopathic arthritis associated macrophage activation syndrome","volume":"119","author":"Mizuta","year":"2019","journal-title":"Cytokine"},{"key":"2021121023214974400_cei13543-bib-0019","first-page":"823","article-title":"Interleukin 18 as a marker of disease activity and severity in patients with juvenile idiopathic arthritis","volume":"34","author":"Lotito","year":"2007","journal-title":"J Rheumatol"},{"key":"2021121023214974400_cei13543-bib-0020","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/rheumatology\/keq133","article-title":"Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis","volume":"49","author":"Shimizu","year":"2010","journal-title":"Rheumatology"},{"key":"2021121023214974400_cei13543-bib-0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLOS Med"},{"key":"2021121023214974400_cei13543-bib-0022","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"2021121023214974400_cei13543-bib-0023","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1172\/JCI129301","article-title":"Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases","volume":"130","author":"de Jesus","year":"2020","journal-title":"J Clin Invest"},{"key":"2021121023214974400_cei13543-bib-0024","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/cei.13026","article-title":"Characteristic elevation of soluble TNF receptor II : I ratio in macrophage activation syndrome with systemic juvenile idiopathic arthritis","volume":"191","author":"Shimizu","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"2021121023214974400_cei13543-bib-0025","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clim.2015.06.005","article-title":"Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"160","author":"Shimizu","year":"2015","journal-title":"Clin Immunol"},{"key":"2021121023214974400_cei13543-bib-0026","doi-asserted-by":"crossref","first-page":"108252","DOI":"10.1016\/j.clim.2019.108252","article-title":"Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"208","author":"Takakura","year":"2019","journal-title":"Clin Immunol"},{"key":"2021121023214974400_cei13543-bib-0027","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/rheumatology\/kez282","article-title":"IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome","volume":"59","author":"Yasin","year":"2020","journal-title":"Rheumatology"},{"key":"2021121023214974400_cei13543-bib-0028","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cyto.2019.03.001","article-title":"Cytokine profile of macrophage activation syndrome associated with Kawasaki disease","volume":"119","author":"Jinkawa","year":"2019","journal-title":"Cytokine"},{"key":"2021121023214974400_cei13543-bib-0029","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/01.mph.0000134465.86671.2e","article-title":"Increased IL-16 levels in hemophagocytic lymphohistiocytosis","volume":"26","author":"Takada","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"key":"2021121023214974400_cei13543-bib-0030","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1046\/j.1365-2141.1999.01504.x","article-title":"Oversecretion of IL-18 in haemophagocytic lymphohistiocytosis: a novel marker of disease activity","volume":"106","author":"Takada","year":"1999","journal-title":"Br J Haematol"},{"key":"2021121023214974400_cei13543-bib-0031","doi-asserted-by":"crossref","first-page":"E46","DOI":"10.1002\/pbc.24480","article-title":"Cytokine profiles in children with primary Epstein\u2013Barr virus infection","volume":"60","author":"Wada","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"2021121023214974400_cei13543-bib-0032","first-page":"55","article-title":"Neuron-specific enolase in hemophagocytic lymphohistiocytosis: a potential indicator for macrophage activation?","volume":"72","author":"Honda","year":"2000","journal-title":"Int J Hematol"},{"key":"2021121023214974400_cei13543-bib-0033","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.4049\/jimmunol.1701628","article-title":"Deletion of inflammasome components is not sufficient to prevent fatal inflammation in models of familial hemophagocytic lymphohistiocytosis","volume":"200","author":"Fauteux-Daniel","year":"2018","journal-title":"J Immunol"},{"key":"2021121023214974400_cei13543-bib-0034","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3389\/fimmu.2012.00239","article-title":"Protection from inflammatory organ damage in a murine model of hemophagocytic lymphohistiocytosis using treatment with IL-18 binding protein","volume":"3","author":"Chiossone","year":"2012","journal-title":"Front Immunol"},{"key":"2021121023214974400_cei13543-bib-0035","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood-2017-06-789552","article-title":"Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice","volume":"131","author":"Girard-Guyonvarc'h","year":"2018","journal-title":"Blood"},{"key":"2021121023214974400_cei13543-bib-0036","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/rheumatology\/kez284","article-title":"IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome","volume":"59","author":"Yasin","year":"2020","journal-title":"Rheumatology"},{"key":"2021121023214974400_cei13543-bib-0037","first-page":"840","article-title":"Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease","volume":"77","author":"Gabay","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2021121023214974400_cei13543-bib-0038","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"2021121023214974400_cei13543-bib-0039","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/cid\/ciaa248","article-title":"Dysregulation of immune response in patients with COVID-19 in Wuhan, China","volume":"71","author":"Qin","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021121023214974400_cei13543-bib-0040","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"2021121023214974400_cei13543-bib-0041","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"2021121023214974400_cei13543-bib-0042","article-title":"Inflammation profiling of critically ill coronavirus disease 2019 patients","volume":"2","author":"Fraser","year":"2020","journal-title":"Crit Care Explor"},{"key":"2021121023214974400_cei13543-bib-0043","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140289","article-title":"Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis","volume":"5","author":"Wilson","year":"2020","journal-title":"JCI Insight"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cei.13543","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cei.13543","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/203\/2\/174\/41635219\/cei13543.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/203\/2\/174\/41635219\/cei13543.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T11:25:10Z","timestamp":1641036310000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/203\/2\/174\/6403024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,23]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,11,23]]},"published-print":{"date-parts":[[2021,1,13]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.13543","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2]]},"published":{"date-parts":[[2020,11,23]]}}}